1 study found for:    gog-0186K
Show Display Options
Rank Status Study
1 Active, not recruiting Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: cabozantinib-s-malate;   Drug: paclitaxel;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years